Assessments of Sarcopenia Prevalence in Chronic Heart Failure Patients and in Subjects Before TAVI
- Conditions
- Chronic Heart FailureSarcopenia
- Interventions
- Diagnostic Test: Assessment of sarcopenia prevalence
- Registration Number
- NCT03153774
- Lead Sponsor
- University Hospital, Clermont-Ferrand
- Brief Summary
The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
The loss of muscle mass in chronic heart failure patients is a prognostic factor for sarcopenia. The purpose was to identify in these patients signs of sarcopenia for a better management.
- Detailed Description
Age-related muscle loss, termed sarcopenia, affects 10% of elderly subjects aged 60-70 years and more than 30% above the age of 80. The concept of sarcopenia has been supported by the recent findings of muscular atrophy which was related to the decrease of protein synthesis because of the "anabolic resistance", affecting the muscular fibers type II. In fact, sarcopenia could be a consequence of chronic disease and not only an issue in the elderly people. The diagnosis is assessed by the weak muscle mass and the muscle strength and function. A description of these muscle parameters has been described in a study of 200 patients with NYHA class II-III and showed that 19,5 % have a decrease in muscle mass. They also showed that these patients have a lower functional ability. These findings prompted us to investigate the prevalence of sarcopenia in chronic heart failure subjects for a better management of these patients.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 300
- Major patients (>18 years)
- Men or women
- Hospitalized in pre- trans aortic valvular implantation assessment in the cardiology department of the university hospital centre of Clermont-Ferrand or
- Patients with chronic heart failure in charge in the hospital of Clermont-Ferrand or convalescence in the pneumocardiological clinic of Durtol
- Patient not affiliated to social security
- Inability to understand the information consent letter
- Not having signed informed consent
- Has a mental or legal incapacitation and is unable to provide informed consent.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Heart failure patients Assessment of sarcopenia prevalence The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation. TAVI patients Assessment of sarcopenia prevalence The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
- Primary Outcome Measures
Name Time Method Bioimpedance analysis data at day 1 Fat-free mass and body fat mass will be combined to report BMI in Kg/m2
Short physical performance battery at day 1 Balance test, 4-min walking test, 5 times getting-up test
Handgrip test at day 1
- Secondary Outcome Measures
Name Time Method Trans-thoracic echography at day 1 Parameter which may interfere with sarcopenia
complete blood count CBC (white blood cells in Giga/L and red blood cells in Tera/L) at day 1 Measure of inflammation
NT-ProBNP in ng/L at day 1 Measure of inflammation
CRP in mg/L at day 1 Measure of inflammation
Blood draw for serum creatinine in umol/L at day 1 Measure of inflammation
platelets in Giga/L at day 1 Measure of inflammation
urea in mmol/L at day 1 Measure of inflammation
albumin in g/L at day 1 Measure of inflammation
Electrocardiogram at day 1 Parameter which may interfere with sarcopenia
Trial Locations
- Locations (1)
CHU Clermont-Ferrand
🇫🇷Clermont-Ferrand, Auvergne, France